![]() |
市场调查报告书
商品编码
1949466
切向流过滤市场 - 全球产业规模、份额、趋势、机会及预测(按产品、膜材料、技术、应用、最终用户、地区和竞争格局划分),2021-2031年Tangential Flow Filtration Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Membrane Material, By Technique, By Application, By End User, By Region & Competition, 2021-2031F |
||||||
全球切向流过滤市场预计将从 2025 年的 25.1 亿美元大幅成长至 2031 年的 51.3 亿美元,复合年增长率为 12.65%。
在此分离过程中,流体平行于多孔膜流动,防止溶质积聚,这对于生物分子的连续纯化至关重要。市场成长的根本驱动力在于全球生物製药和生物相似药产量的不断增长,而这些产品需要可靠的下游加工流程来确保产品纯度。此外,生物製造领域向一次性技术的转变也透过最大限度地降低交叉污染风险和减少清洁验证所需的停机时间来支持这一增长。
| 市场概览 | |
|---|---|
| 预测期 | 2027-2031 |
| 市场规模:2025年 | 25.1亿美元 |
| 市场规模:2031年 | 51.3亿美元 |
| 复合年增长率:2026-2031年 | 12.65% |
| 成长最快的细分市场 | PES |
| 最大的市场 | 北美洲 |
然而,市场面临严峻的挑战,因为膜更换和系统污染带来的高昂营运成本可能会对契约製造生产商的预算造成压力。推动这些加工需求的产业规模显而易见:根据欧洲製药工业协会联合会(EFPIA)的数据,预计到2024年,以研发为基础的製药业在欧洲的研发投入将达到约550亿欧元。
生物製药产业的快速扩张是市场的主要驱动力,推动了对能够处理高效价复杂分子的高效分离系统的需求。治疗药物生产的激增也体现在监管活动上,美国食品药物管理局(FDA) 在 2024 年核准了50 种新药(如 2025 年 1 月的报告所示),这表明生物製药新进者拥有良好的发展环境。这一行业成长正转化为专注于过滤技术公司的实际经济效益。例如,Repligen 在 2025 年 2 月的收益报告中宣布,其过滤产品收入在本财年增长了 3,160 万美元。
此外,由于越来越多的公司依赖外包给契约製造组织 (CDMO) 来降低自建工厂所需的高昂资本成本,市场格局正在重塑。 CDMO 正在积极扩大产能以满足多元化的客户需求,这需要功能多样且扩充性的过滤系统。三星生物製剂的业绩尤其反映了这一趋势,该公司在 2025 年 1 月创下了超过 4 兆韩元的年度合併销售额的历史新高。这相当于同比增长 23%,主要得益于生产合约的扩大,从而确保了过滤设备供应商的持续收入。
全球切向流过滤市场面临的主要障碍是膜更换和系统堵塞相关的高昂营运成本。这些持续的支出给生物製药生产商,尤其是预算严格的契约製造组织(CMO),带来了沉重的财务负担。在复杂生物製药的纯化过程中,过滤膜不可避免地会劣化和阻塞,需要频繁更换,从而增加了整体拥有成本。此外,维护所需的停机时间会扰乱生产计划,降低工厂的整体产能。
在製药业,成本敏感度至关重要,因为该行业本身就面临着巨大的财务压力,需要有效率地将产品推向市场。根据欧洲製药工业协会联合会(EFPIA)2024年的数据,新化学实体或生物製药的研发成本预计将达到31.3亿欧元。如此天文数字般的研发成本意味着下游环节的效率低下,包括高成本的维护费用,都将受到严格审查,这会阻碍小规模製造商采用先进的过滤系统,并减缓整个市场的成长。
向连续灌注式生物製程的转变正在从根本上改变市场格局,这需要能够在无需循环的情况下进行高浓度处理的系统。生物製药製造商正在加速采用单一途径切向流过滤(SPTFF) 技术,以实现连续下游处理。与传统的间歇式方法相比,SPTFF 可显着减少设施面积,并最大限度地降低敏感生物製药的剪切应力。这一转变正在为技术供应商带来可观的收入。例如,赛多利斯 (Sartorius) 在 2025 年 1 月的中期财务报告中指出,其生物製程解决方案部门的销售额为 26.9 亿欧元,并将这一业绩归功于支持先进治疗方法和连续生产的产品。
同时,切向流过滤在mRNA和核酸生产中的广泛应用,正在创造清晰的高价值成长路径,特别是在脂质奈米颗粒包覆和缓衝液交换领域。这些基因组药物需要精确的过滤控制以维持颗粒完整性,从而推动市场转向与特定溶剂系统相容的专用耗材。例如,龙沙公司(Lonza)公布2025年1月销售额达66亿瑞士法郎,反映了产业的稳定性。该公司细胞和基因技术部门实现了稳健的基础成长,抵消了疫情相关mRNA需求正常化的影响。
The Global Tangential Flow Filtration Market is projected to expand significantly, growing from USD 2.51 Billion in 2025 to USD 5.13 Billion by 2031 at a CAGR of 12.65%. This separation process, where a fluid stream flows parallel to a porous membrane to prevent solute buildup, is essential for the continuous purification of biomolecules. The market's growth is fundamentally driven by the rising global production of biologics and biosimilars, which necessitates reliable downstream processing to ensure product purity. Additionally, the shift toward single-use technologies in biomanufacturing supports this expansion by minimizing cross-contamination risks and reducing the downtime required for cleaning validation.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 2.51 Billion |
| Market Size 2031 | USD 5.13 Billion |
| CAGR 2026-2031 | 12.65% |
| Fastest Growing Segment | PES |
| Largest Market | North America |
However, the market faces a substantial challenge due to high operational expenses associated with membrane replacement and system fouling, which can strain the budgets of contract manufacturing organizations. The financial magnitude of the sector driving these processing needs is evident; according to the European Federation of Pharmaceutical Industries and Associations, the research-based pharmaceutical industry invested approximately €55,000 million in R&D in Europe in 2024.
Market Driver
The rapid expansion of the biopharmaceutical industry serves as a primary catalyst for the market, increasing the demand for efficient separation systems capable of handling higher titers and complex molecules. This surge in therapeutic output is reflected in regulatory activities, such as the U.S. Food and Drug Administration's approval of 50 novel drugs in 2024, as noted in their January 2025 report, signaling a robust environment for new biologic entrants. This industry growth translates into tangible financial gains for filtration specialists; for instance, Repligen Corporation reported a $31.6 million increase in filtration product revenue for the fiscal year in its February 2025 financial results.
Furthermore, the increasing reliance on outsourcing to Contract Manufacturing Organizations is reshaping the market landscape as companies seek to mitigate the massive capital costs of internal facility construction. CDMOs are aggressively expanding production capacities to accommodate diverse client pipelines, necessitating versatile and scalable filtration systems. This trend is exemplified by Samsung Biologics, which achieved record full-year consolidated revenue exceeding 4 trillion won in January 2025-a 23% increase year-over-year-driven largely by expanded manufacturing contracts that ensure continuous revenue for filtration vendors.
Market Challenge
A significant barrier for the Global Tangential Flow Filtration Market is the high operational expense linked to membrane replacement and system fouling. These recurring costs create a severe financial burden for biopharmaceutical manufacturers, particularly Contract Manufacturing Organizations that operate under strict budget constraints. Because filtration membranes inevitably degrade or foul during the purification of complex biologics, the need for frequent replacement increases the total cost of ownership, while the required downtime for maintenance impedes production schedules and reduces overall facility throughput.
This cost sensitivity is critical in an industry already facing immense financial pressure to bring products to market efficiently. According to the European Federation of Pharmaceutical Industries and Associations in 2024, the estimated cost to research and develop a new chemical or biological entity reached €3,130 million. Such astronomical development expenditures mean that downstream processing inefficiencies, including costly maintenance, are heavily scrutinized, often deterring smaller manufacturers from adopting advanced filtration systems and slowing broader market growth.
Market Trends
The shift toward continuous and perfusion-based bioprocessing is fundamentally altering the market by necessitating systems capable of high-concentration processing without recirculation. Biopharmaceutical manufacturers are increasingly adopting single-pass tangential flow filtration (SPTFF) to enable continuous downstream operations, which significantly reduces facility footprint and minimizes shear stress on sensitive biologics compared to traditional batch methods. This transition is driving substantial revenue for technology providers; Sartorius, for example, reported Bioprocess Solutions Division sales of 2,690 million euros in its January 2025 preliminary results, attributing the performance to products supporting advanced therapies and continuous manufacturing.
Simultaneously, the widespread application of tangential flow filtration in mRNA and nucleic acid manufacturing is creating a distinct high-value growth avenue, particularly for lipid nanoparticle encapsulation and buffer exchange. These genomic medicines require precise filtration control to maintain particle integrity, pushing the market toward specialized consumables compatible with unique solvent systems. Highlighting the sector's stability, Lonza reported sales of CHF 6.6 billion in January 2025, with its Cell & Gene Technologies division delivering strong underlying growth that compensated for the normalization of pandemic-related mRNA demand.
Report Scope
In this report, the Global Tangential Flow Filtration Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Tangential Flow Filtration Market.
Global Tangential Flow Filtration Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: